Ian F. C. Mckenzie
#159,770
Most Influential Person Now
Ian F. C. Mckenzie's AcademicInfluence.com Rankings
Ian F. C. Mckenziechemistry Degrees
Chemistry
#4599
World Rank
#5683
Historical Rank
Nanotechnology
#156
World Rank
#156
Historical Rank
Chemical Engineering
#591
World Rank
#611
Historical Rank
Ian F. C. Mckenzieengineering Degrees
Engineering
#6833
World Rank
#8181
Historical Rank
Biomedical Engineering
#635
World Rank
#645
Historical Rank
Applied Physics
#2260
World Rank
#2299
Historical Rank
Download Badge
Chemistry Engineering
Ian F. C. Mckenzie's Degrees
- Masters Chemical Engineering Stanford University
- Bachelors Chemistry University of California, Berkeley
Why Is Ian F. C. Mckenzie Influential?
(Suggest an Edit or Addition)Ian F. C. Mckenzie's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Size-Dependent Immunogenicity: Therapeutic and Protective Properties of Nano-Vaccines against Tumors1 (2004) (613)
- Cytotoxic T-lymphocytes derived from patients with breast adenocarcinoma recognize an epitope present on the protein core of a mucin molecule preferentially expressed by malignant cells. (1991) (393)
- Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein. (1997) (267)
- Cells mediating graft rejection in the mouse. I. Lyt-1 cells mediate skin graft rejection (1981) (218)
- Murine lymphocyte surface antigens. (1979) (216)
- Resistance and susceptibility of mice to bacterial infection: genetics of listeriosis (1978) (204)
- Ly and Ia antigen phenotypes of T cells involved in delayed-type hypersensitivity and in suppression (1976) (203)
- Oxidative/reductive conjugation of mannan to antigen selects for T1 or T2 immune responses. (1995) (190)
- Increased expression of IL-4 and IL-10 and decreased expression of IL-2 and interferon-gamma in long-surviving mouse heart allografts after brief CD4-monoclonal antibody therapy. (1995) (186)
- Tissue expression, structure and function of the murine Ly‐6 family of molecules (1995) (175)
- Role of the mannose receptor in the immune response. (2001) (164)
- Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen. (1997) (153)
- Mannan-MUC1–Pulsed Dendritic Cell Immunotherapy: A Phase I Trial in Patients with Adenocarcinoma (2006) (153)
- Cell-mediated immune responses to MUC1 fusion protein coupled to mannan. (1996) (145)
- Resistance and susceptibility of mice to bacterial infection: course of listeriosis in resistant or susceptible mice (1978) (131)
- Ex vivo targeting of the macrophage mannose receptor generates anti-tumor CTL responses. (2000) (119)
- Identification and quantification of complement regulator CD46 on normal human tissues. (1993) (107)
- Cellular origins of co-stimulator (IL2) and its activity in cytotoxic T lymphocyte responses. (1980) (101)
- Which T cells cause graft rejection (1982) (99)
- Polymorphic expression of CD46 protein isoforms due to tissue-specific RNA splicing. (1993) (92)
- Up to 15-year clinical follow-up of a pilot Phase III immunotherapy study in stage II breast cancer patients using oxidized mannan-MUC1. (2013) (91)
- Cutaneous leishmaniasis in mice: disease patterns in reconstituted nude mice of several genotypes infected with Leishmania tropica. (1980) (87)
- Studies of methotrexate-monoclonal antibody conjugates for immunotherapy. (1985) (85)
- In vivo and in vitro effects of monoclonal antibody to Ly antigens on immunity to infection. (1982) (83)
- Antibody Conjugates for the Treatment of Cancer (1992) (83)
- A human breast tissue-associated antigen detected by a monoclonal antibody. (1983) (83)
- IMMUNOSCINTIGRAPHY FOR DETECTION OF LYMPH NODE METASTASES FROM BREAST CANCER (1984) (80)
- The detection of β-adrenoceptors on murine lymphocytes (1981) (79)
- A new breast carcinoma antigen defined by a monoclonal antibody. (1985) (72)
- CTL in mice immunized with human mucin 1 are MHC-restricted. (1995) (70)
- Tumor immunotherapy in the mouse with the use of 131I-labeled monoclonal antibodies. (1984) (64)
- Monoclonal antibodies to B cells. (1983) (61)
- Selection and characterization of MUC1‐specific CD8+ T cells from MUC1 transgenic mice immunized with dendritic‐carcinoma fusion cells (2000) (60)
- The effect of temperature on the binding kinetics and equilibrium constants of monoclonal antibodies to cell surface antigens. (1990) (60)
- Cooperation between mouse T-cell subpopulations in the cell-mediated response to a natural poxvirus pathogen. (1976) (59)
- Flow cytometric measurement of intracellular cytokines detects immune responses in MUC1 immunotherapy. (2000) (59)
- Acute destruction by humoral antibody of rat skin grafted to mice. (1973) (58)
- Macrophage procoagulant activity as a measure of cell-mediated immunity in the mouse. (1983) (56)
- MUC1 and breast cancer. (1999) (56)
- Which T cells cause graft rejection? (1982) (55)
- Lymphocyte antigens: Ly-4, Ly-6, and Ly-7. (1977) (53)
- Use of vasoactive agents to increase tumor perfusion and the antitumor efficacy of drug-monoclonal antibody conjugates. (1987) (52)
- Specific targeting of chlorambucil to tumors with the use of monoclonal antibodies. (1986) (51)
- Phase-I study of synthetic muc1 peptides in breast-cancer. (1995) (50)
- Breast cancer immunotherapy: Current status and future prospects (1996) (48)
- Selective enhancement of antitumor activity of N-acetyl melphalan upon conjugation to monoclonal antibodies. (1987) (47)
- VARIATIONS IN THE RESPONSES OF C57BL/10J AND A/J MICE TO SHEEP RED BLOOD CELLS (1972) (47)
- DEPOSITS OF IMMUNOGLOBULIN AND FIBRIN IN HUMAN ALLOGRAFTED KIDNEYS (1968) (46)
- Peritoneal cell population of mice infected with Mesocestoides corti as a source of eosinophils. (1979) (46)
- Specificity, Ly phenotype, and H-2 compatibility requirements of effector cells in delayed-type hypersensitivity responses to murine influenza virus infection (1980) (46)
- Production of anti-breast cancer monoclonal antibodies using a glutathione-S-transferase-MUC1 bacterial fusion protein. (1993) (45)
- Different membrane cofactor protein (CD46) isoforms protect transfected cells against antibody and complement mediated lysis. (1993) (45)
- Monoclonal antibodies to human colon and colorectal carcinoma. (1983) (44)
- Engineering of recombinant soluble CD46: an inhibitor of complement activation. (1996) (43)
- H‐2 COMPLEX AND Ia ANTIGENS ON CELLS DISSOCIATED FROM MOUSE THYROID GLANDS AND ISLETS OF LANGERHANS (1980) (43)
- Carcinogenicity of tumor cell populations: origin of a putative H-2 isoantigenic loss variant tumor. (1980) (43)
- Immune function in aged mice. V. Role of suppressor cells. (1980) (41)
- Heterogeneity of the human transferrin receptor and use of anti‐transferrin receptor antibodies to detect tumours in vivo (1987) (41)
- Immunochemotherapy of a murine thymoma with the use of idarubicin monoclonal antibody conjugates. (1988) (40)
- Cellular mucins: targets for immunotherapy. (1994) (39)
- Definition of MHC-restricted CTL epitopes from non-variable number of tandem repeat sequence of MUC1. (2000) (39)
- Measles virus receptor properties are shared by several CD46 isoforms differing in extracellular regions and cytoplasmic tails. (1994) (39)
- Cells mediating graft rejection in the mouse. II. The Ly phenotypes of cells producing tumor allograft rejection. (1982) (38)
- Increased antitumor effect of immunoconjugates and tumor necrosis factor in vivo. (1988) (38)
- Comparison of mammary serum antigen (MSA) and CA15-3 levels in the serum of patients with breast cancer. (1987) (37)
- Dendritic cell immunotherapy: clinical outcomes (2014) (36)
- Recognition of an octapeptide sequence by multiple Galα(1,3)Gal‐binding proteins (1996) (36)
- Chemoimmunoconjugates for the treatment of cancer. (1994) (34)
- CR3 receptor on platelets and its role in the prostaglandin metabolic pathway (1987) (33)
- Induction of T1 (cytotoxic lymphocyte) and/or T2 (antibody) responses to a mucin-1 tumour antigen. (1997) (32)
- An analysis of T lymphocyte subsets in tumour-transplanted mice on the basis of Lyt antigenic markers and functions. (1982) (31)
- Immunotherapy with mannan-MUC1 and IL-12 in MUC1 transgenic mice. (2000) (31)
- Foam cells in the renal glomerulus (1969) (30)
- Immunological enhancement of skin grafts in the mouse. (1972) (30)
- Delayed-type hypersensitivity and allograft rejection in the mouse: correlation of effector cell phenotype. (1982) (30)
- THE ROLE OF T4+ AND LY‐2+ CELLS IN SKIN GRAFT REJECTION IN THE MOUSE (1987) (29)
- A monoclonal anti-pan-T-cell antibody. In vitro and in vivo studies. (1983) (29)
- Expression of MUC2 Gene Product in Mucinous Carcinoma of the Breast: Comparison with Invasive Ductal Carcinoma (1995) (29)
- Tumor localization by combinations of monoclonal antibodies in a new human colon carcinoma cell line (LIM1899). (1990) (29)
- A comparison of skin and heart graft rejection patterns in H-2 mutant mice. (1980) (29)
- Upregulation of complement regulators MCP (CD46), DAF (CD55) and protectin (CD59) in arthritic joint disease. (1994) (29)
- A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer (2014) (29)
- Localization of human colorectal tumor xenografts in the nude mouse with the use of radiolabeled monoclonal antibody. (1983) (28)
- The immunogenicity of MUC1 peptides and fusion protein. (1995) (27)
- The mode of action of methotrexate‐monoclonal antibody conjugates (1987) (27)
- Genetic control of sensitivity to Moloney leukemia virus in mice. IV. Phenotypic heterogeneity of the leukemic mice. (1980) (27)
- Human lymphocytotoxic and haemagglutinating activity against sheep and pig cells. (1968) (25)
- T cell‐dependent suppression of antibody production. I. Characteristics of suppressor T cells following tolerance induction (1978) (25)
- Phase I clinical trial of drug-monoclonal antibody conjugates in patients with advanced colorectal carcinoma: a preliminary report. (1989) (24)
- Effect of tumor necrosis factor on the antitumor efficacy and toxicity of aminopterin-monoclonal antibody conjugates: parameters for optimization of therapy. (1990) (24)
- Oxidised mannan antigen conjugates preferentially stimulate T1 type immune responses. (1998) (24)
- Evidence that Thy‐1 and Ly‐5 (T‐200) antigens interact with sulphated carbohydrates (1988) (24)
- Ly-4.2: a cell membrane alloantigen of murine B lymphocytes. I. Population studies. (1975) (23)
- Mimics and cross reactions of relevance to tumour immunotherapy. (1999) (23)
- Induction of humoral and cellular responses in cynomolgus monkeys immunised with mannan-human MUC1 conjugates. (1999) (23)
- Anti‐tumour activity of aminopterin‐monoclonal antibody conjugates; in vitro and in vivo comparison with methotrexate‐monoclonal antibody conjugates (1987) (23)
- ANTIBODY PRODUCTION IN IMMUNOSUPPRESSED RECIPIENTS OF RENAL ALLOGRAFTS (1969) (23)
- Generation of cellular immune responses to antigenic tumor peptides (2000) (23)
- Effects of fourH-2K mutations on virus-induced antigens recognized by cytotoxic T cells (1976) (23)
- Novel synthesis and in vitro characterization of disulfide-linked ricin-monoclonal antibody conjugates devoid of galactose binding activity. (1988) (22)
- Cytokine production from murine CD4 and CD8 cells after mannan-MUC1 immunization. (1999) (21)
- The acceptability of pig organ xenografts to patients awaiting a transplant (1997) (21)
- Comparison of in vitro cell binding characteristics of four monoclonal antibodies and their individual tumor localization properties in mice. (1990) (21)
- Chimeric (mouse/human) anti-colon cancer antibody c30.6 inhibits the growth of human colorectal cancer xenografts in scid/scid mice. (1994) (20)
- Coupling of the 99mtechnetium-nitrido group to monoclonal antibody and use of the complexes for the detection of tumors in mice. (1986) (20)
- Monoclonal antibodies to a MUC 4 peptide react with lung cancer. (1997) (20)
- TOPICAL DNCB THERAPY FOR RESISTANT WARTS (1978) (20)
- The immune response of mice and cynomolgus monkeys to macaque mucin 1-mannan. (2000) (19)
- Regulation of cell-mediated immunologic reactivity to Moloney murine sarcoma virus-induced tumors. II. Nature of blocking and unblocking factors in serum. (1981) (19)
- A phase I/II study of the intralesional injection of ricin-monoclonal antibody conjugates in patients with hepatic metastases. (1994) (19)
- Murine monoclonal antibodies in breast cancer: An overview (1988) (19)
- Evaluation of MSA as a serum marker in breast cancer: a comparison with CEA. (1988) (18)
- Translation is enhanced after silent nucleotide substitutions in A+T- rich sequences of the coding region of CD46 cDNA. (1996) (18)
- Application of mammary serum antigen assay in the management of breast cancer: A preliminary report (1988) (18)
- Getting into the groove: unusual features of peptide binding to MHC class I molecules and implications in vaccine design. (2001) (18)
- Visualization of metastases from colon carcinoma using an lodine 131‐radiolabeled monoclonal antibody (1986) (17)
- HU LY‐M3—A HUMAN LEUKOCYTE ANTIGEN (1983) (17)
- Tolerance induction with anti-CD8 monoclonal antibodies in the mouse heart transplant model. (1993) (16)
- In vitro antitumor activity of 2'-deoxy-5-fluorouridine-monoclonal antibody conjugates. (1991) (16)
- Suppression of cell-mediated immunity following oral feeding of mice with palmyrah (Borassus flabellifer L) flour. (1985) (16)
- CELLS MEDIATING GRAFT REJECTION IN THE MOUSE: III. Ly‐1 Precursor T Cells Generate Skin Graft Rejection (1982) (16)
- Purification and biochemical characterisation of a novel breast carcinoma associated mucin-like glycoprotein defined by antibody 3E1.2. (1989) (16)
- Functional characterisation of alternatively spliced CD46 cytoplasmic tails. (1992) (16)
- Production of monoclonal antibodies to serum antigens in colorectal carcinoma. (1988) (15)
- IgM Activity in Human Lymphotoxic Antisera after Renal Transplantation (1969) (15)
- Specific in vitro anti‐tumour activity of methotrexate‐monoclonal antibody conjugates prepared using human serum albumin as an intermediary (1988) (14)
- Deposits of immunoglobulin and fibrin in human allografted kidneys. (1969) (14)
- Idarubicin-anti-CD3: a new immunoconjugate that induces alloantigen-specific tolerance in mice. (1997) (14)
- Antitumor effect of 2'-deoxy-5-fluorouridine conjugates against a murine thymoma and colon carcinoma xenografts. (1992) (14)
- The in vitro and in vivo anti-tumour activity of N-AcMEL-(Fab')2 conjugates. (1987) (14)
- The diagnosis of human tumours with monoclonal antibodies. (1985) (14)
- Prolonged survival of mouse cardiac allografts after CD4 or CD8 monoclonal antibody therapy is associated with selective intragraft cytokine protein expression: interleukin (IL)-4 and IL-10 but not IL-2 or interferon-gamma. (1993) (14)
- Fetal pig islet xenografts in NOD/Lt mice: The effect of peritransplant anti‐CD4 monoclonal antibody and graft immunomodification on graft survival, and lack of expression of Gal(α1–3)Gal on endocrine cells (1995) (14)
- Induction and Ly phenotype of suppressor T cells in mice during primary infection with dengue virus. (1984) (13)
- Aspects of cancer immunotherapy (2003) (12)
- Xenotransplantation. This new form of treatment might benefit millions. (2000) (12)
- CELLS MEDIATING GRAFT REJECTION IN THE MOUSE: IV. The Ly‐5, 6, and 7 Effector Cell Phenotype (1982) (12)
- Tumour necrosis factor increases tumour uptake of co-administered antibody-carboxypeptidase G2 conjugate. (1993) (12)
- Tumor-associated antigens--an overview. (1985) (12)
- A comparison of the cytolytic action of guinea pig and rabbit complement on sensitized nucleated mouse cells. (1973) (12)
- Murine cardiac allograft survival following treatment of recipients with monoclonal anti-L3T4 or Ly-2 antibodies. (1987) (11)
- Monoclonal antibodies in clinical medicine--a review. (1983) (11)
- Mechanism of skin graft enhancement in the mouse. (1971) (11)
- Enhanced antitumour effects using a combination of two antibodies conjugated to different drugs. (1994) (11)
- Structural implications for the design of molecular vaccines. (2000) (10)
- Coordinate functions of multiple complement regulating molecules, CD46, CD55, and CD59. (1994) (10)
- Milestones in the molecular structure of the major histocompatibility complex. (1997) (10)
- Monoclonal antibodies to drugs--digoxin. (1983) (10)
- Investigation of Alternative Mechanisms of Collagen - Induced Platelet Activation by Using Monoclonal Antibodies to Glycoprotein IIb-IIIa and Fibrinogen (1986) (9)
- Lyt antigens on the T cells specific for minor histocompatibility antigens: suppression by a Lyt-1+2- regulator. (1981) (9)
- The prognostic value of immunoperoxidase staining with monoclonal antibodies NCRC-11 and 3E1.2 in breast cancer. (1991) (9)
- Lyt phenotype and H-2 compatibility requirements of effector cells in the delayed-type hypersensitivity response to dengue virus infection (1984) (9)
- Antibody production in immunosuppressed recipients of renal allografts. (1970) (9)
- Fetal pig xenografts in NOD/Lt mice: lack of expression of Gal(alpha 1-3)Gal on endocrine cells and the effect of peritransplant anti-CD4 monoclonal antibody and graft immunomodification on graft survival. (1995) (9)
- Accessory cells in the in vitro generation of type C virus-specific T killer lymphocytes. II. Demonstration of a T helper cell in the spleen of in vivo primed mice. (1981) (9)
- EVIDENCE THAT AN ANTHRACYCLINE‐ANTI-CD8 IMMUNOCONJUGATE, IDARUBICIN‐ANTI-LY‐2.1, PROLONGS HEART ALLOGRAFT SURVIVAL IN MICE (1993) (9)
- In vitro and in vivo evaluation of human tumor necrosis factor-alpha (hTNFalpha) chemically conjugated to monoclonal antibody. (1998) (8)
- Molecular characterization of the polymorphic expression of CD46: a cell surface molecule protecting cells from complement attack. (1992) (8)
- Prolongation of murine cardiac allografts following treatment of graft recipients with monoclonal anti-L3T4 and Ly-2 antibodies. (1987) (8)
- Properties of monoclonal antibodies to human tumor necrosis factor alpha (TNF alpha). (1992) (8)
- Transfer of cell-mediated immunity with cell-free leukocyte extracts. III. Demonstration of Ia antigens in the specific component. (1980) (8)
- THE EFFECT OF THE H‐2 GENE DOSE ON THE REJECTION OF SKIN GRAFTS (1973) (8)
- The key role of Lyt-1+ cells in skin graft rejection in the mouse. (1981) (8)
- Biopsy features of early acute rejection in cadaveric renal grafts. (1969) (8)
- Mannan Mucin-1 Peptide Immunization: Influence of Cyclophosphamide and the Route of Injection. (2001) (7)
- Immunogenicity and enhancement of normal and tumor tissue in the mouse. (1973) (7)
- Tumour visualisation using a radiolabelled monoclonal antibody. (1983) (7)
- The molecular basis of CD46 polymorphic expression and demonstration of a protective role against lysis by xenosera. (1992) (7)
- Description of a murine B lymphoma tumor-specific antigen. (1984) (7)
- Transfer of cell-mediated immunity with cell-free leukocyte extracts. I. Comparison of in vitro and in vivo assays of cell-mediated immune function. (1980) (7)
- Demonstration of two ovarian tumor-associated antigens in primary and metastatic breast, gastric, and colonic tumors. (1990) (7)
- Antitumor activity of idarubicin-monoclonal antibody conjugates in a disseminated thymic lymphoma model. (1991) (7)
- Detection of Breast Cancer Using the Monoclonal Antibody 3E-1.2 (1985) (7)
- Immunochemotherapy of human colon carcinoma xenografts in nude mice using combinations of idarubicin‐monoclonal antibody conjugates (1993) (7)
- The distribution of the Qa-2 alloantigen on functional T lymphocytes. (1985) (7)
- Detection of Breast Cancer Using the Monoclonal Antibody 3E-1.2 (1985) (7)
- HLA (Class I) antigens on platelets are involved in platelet function (1988) (7)
- Treatment of acute renal allograft rejection with a monoclonal antibody to a T cell antigen (HuLy-m2). (1987) (7)
- A MONOCLONAL ANTIBODY DETECTING A NEW HUMAN T CELL ANTIGEN, HULY‐M2 (1984) (7)
- Comparison of CD4 depleting and nondepleting monoclonal antibodies in the mouse heart allograft model. (1993) (7)
- The use of monoclonal antibody immunoconjugates in cancer therapy. (1994) (7)
- Tolerance in baboon kidney transplantation with total lymphoid irradiation (TLI) and anti-CD3/CD4-idarubicin conjugates. (2001) (7)
- Different h-2 requirements for triggering precursor t-cell induction or lysis by effector t cells defined by the balb/c-h- -2db mutation. (1977) (7)
- Evidence for adaptation of skin grafts in enhanced irradiated mice. (1972) (6)
- The detection of beta-adrenoceptors on murine lymphocytes. (1981) (6)
- EFFECT OF A MONOCLONAL ANTI‐LYT-1.1 ON THE FUNCTIONAL ACTIVITY OF PRECURSOR, EFFECTOR, AND REGULATORY CELLS SPECIFIC FOR MURINE ALLOANTIGENS (1981) (6)
- Serum la Levels During Tumor Growth in Mice and Humans (1981) (6)
- Restriction in adoptive transfer of resistance to Listeria monocytogenes. I. Influence of non-H-2 loci. (1983) (6)
- CD46 (MCP) confers protection from lysis by xenogeneic antibodies. (1993) (6)
- Soluble mouse histocompatibility antigens. (1971) (6)
- Induction of suppressor T cells of antibody formation under conditions that preferentially stimulate DTH. (1980) (5)
- Surface membrane antigens of hemopoietic tumor cell lines and normal marrow progenitor cells. (1981) (5)
- Regulation of cell-mediated immunologic reactivity to Moloney Murine sarcoma virus-induced tumors. III. Further characterization of tumor-specific serum blocking factors. (1982) (5)
- Generation of MUC1 cytotoxic T-cells in mice and epitope mapping. (2000) (5)
- Evidence of different effector t-cell populations for systemic and "local" immunity. (1983) (4)
- Tolerance induction to murine class II MHC molecules by anti-CD4 antibody. (1989) (4)
- The definition of an MB related specificity by a monoclonal antibody. (1983) (4)
- Both class I and class II responsive T cell subsets can separately initiate lethal graft-versus-host disease in H-2-incompatible murine radiation chimeras. (1987) (4)
- IMMUNOSUPPRESSION OF GRAFT REJECTION WITH IDARUBICIN‐MONOCLONAL ANTIBODY CONJUGATES BY ELIMINATION OF T CELL SUBSETS IN VIVO (1988) (4)
- MUC1 immunotherapy against a metastatic mammary adenocarcinoma model: Importance of IFN-gamma (2016) (4)
- High incidence of early leukemic relapse in patients given cyclosporin and T cell depleted HLA-identical sibling marrow transplants for acute leukemia in first remission. (1988) (4)
- Surface markers on the T cells that regulate cytotoxic T-cell responses I. The Ly phenotype of suppressor T cells changes as a function of time, and is distinct from that of helper or cytotoxic T cells. (1980) (4)
- Isolation of a clone for pig beta 2-microglobulin cDNA. (1993) (4)
- Xenotransplantation trials (2002) (4)
- The association of mammary serum antigen (MSA) with the histopathological findings in localised breast cancer. (1988) (4)
- Lymphocyte differentiation as analyzed by the expression of defined cell surface markers. (1978) (4)
- Potentiation of the in vitro cytotoxicity of chlorambucil by monoclonal antibodies. (1986) (4)
- The production and preclinical characterization of a chimeric anti-breast-cancer antibody, cBC2. (1994) (4)
- Studies of H-2 mutations in C57BL/6 and BALB/c mice. (1977) (4)
- Monoclonal Antibodies Reactive with Breast Cancer, Mammary Mucins and Synthetic Peptides (1991) (3)
- Analysis of human bone marrow with monoclonal antibodies. (1985) (3)
- Role of histocompatibility in graft rejection. (1979) (3)
- The cellular uptake and cytotoxicity of chlorambucil‐monoclonal autibody conjugates (1987) (3)
- Tissue-specific expression of CD46 isoforms. (1992) (3)
- NEW ANTI-CD3 AGENTS FOR TRANSPLANTATION TOLERANCE INDUCTION (1998) (3)
- Construction of CD46 minigenes for the production of transgenic mice. (1995) (3)
- Serologic distinction between soluble species-specific and strain-specific transplantation antigens. (1973) (3)
- The isolation and characterization of soluble murine H-2 alloantigens. (1973) (3)
- Leukocyte antigens in renal transplantation. 7. Immediate renal allograft rejection with a negative cross match. (1970) (3)
- Cytotoxic cells may not be necessary for graft rejection (1985) (3)
- Functional characterization of mouse lymphocyte subpopulations identified by their natural binding of bacteria. II. Identification of subpopulations of LY-1 + 2-3-, LY-1-2+3+ and LY-1+2+3+ cells and the localization of specific cytotoxic cells in a subset of LY-1-2+3+ cells . (1979) (3)
- Tissue-specific expression of CD46 protein isoforms due to production of RNA splice variants. (1994) (3)
- Hybridomas and monoclonal antibodies: applications in oncology. (1982) (2)
- B‐Lymphocyte Colony‐forming Cells in the SJL/J Mouse Thymus Graft Repopulation: Independence on Host Thymus and Graft Genotype (1978) (2)
- Infiltrating cells in mouse cardiac allografts after anti-CD4 monoclonal antibody treatment. (1995) (2)
- Molecular analysis of FcR of T cells and other cell types. (1989) (2)
- Serum Ia levels during tumor growth in mice and humans. (1981) (2)
- Preclinical studies with immunoconjugates. (1989) (2)
- Changes in T-cell subsets after renal transplantation in nonimmunosuppressed baboons. (1998) (2)
- The antibody response of rabbits to soluble mouse H-2 antigens. (1972) (2)
- Immunogenicity and enhancement for the private specificities H-2.12,16,20, and 21. (1974) (2)
- REQUIREMENT FOR HELP IN THE GENERATION OF ALLOANTIGEN‐SPECIFIC HELPER CELLS (1985) (2)
- Use of microplates for monolayer tissue cultures. (1969) (2)
- Identification andquantification ofcomplement regulator CD46 on normalhumantissues (1993) (1)
- THE EFFECT OF IDARUBICIN MONOCLONAL ANTIBODY TREATMENT ON FIRST‐SET REJECTION OF MURINE SKIN ALLOGRAFTS (1989) (1)
- Anti-T cell-specific immunoconjugates in mice: in vivo effects. (1989) (1)
- Honorary Membership of International Xenotransplantation Association Conferred Upon Professor Ian F C McKenzie (September 18, 2007) (2008) (1)
- Effect of IL‐4 deletion on cardiac allograft survival in the BALB/c to 129Sv × C57BL/6 strain combination (1998) (1)
- Immunological enhancement can be mediated by anti-Ia and anti-K,D antibodies. (1980) (1)
- Genetic control of the immune response to the H-2Dk private specificity, H-2.32. II. Genetic linkage analysis of a backcross generation. (1978) (1)
- Antitumor activity of idarubicin-monoclonal antibody conjugate on multidrug resistant cells (1993) (1)
- Antisense oligonucleotides decrease expression of human CD46, a regulator of complement. (1993) (1)
- Monoclonal antibody-drug/toxin immunoconjugates in transplantation. (1989) (1)
- Deletion of graft reactive cells by idarubicin-anti-CD8 (Ly-2.1) immunoconjugate: studies in the mouse heart graft model. (1991) (1)
- IN VITRO INVESTIGATION OF HUMAN CELLULAR AND HUMORAL RESPONSES TO CELLS FROM GENETICALLY- MODIFIED PIGS: 679 (2008) (1)
- Immunoradiometric assay for the rapid detection of HLA‐B27 (1988) (1)
- Immunosuppression by aminopterin or idarubicin conjugated to anti-CD8 in the mouse heart allograft model. (1992) (1)
- A Monoclonal antibody involved in platelet activation (1984) (1)
- Investigation of T and natural killer cell function with monoclonal antibodies. (1986) (1)
- Prolonged survival of baboon renal allografts using idarubicin-conjugated anti-CD4 monoclonal antibodies. (1999) (1)
- Synthesis and analysis of peptide to murine CD4 molecules. (1989) (1)
- Mouse Soluble Transplantation Antigens1 (1971) (1)
- Immunology. (Book Reviews: Transplantation Antigens. Markers of Biological Individuality) (1973) (1)
- Differentiation of antigenic markers on B cells and on antibody-forming cells. (1975) (1)
- Role of monoclonal antibodies in the therapy of solid tumours. (1988) (1)
- Idarubicin-anti-CD3 reduces vascular disease in mouse cardiac allografts. (1999) (1)
- Mannan-mediated Delivery of Protein, DNA, RNA to Antigen Presenting Cells (2005) (0)
- Prolongation of fetal pancreas allograft survival in mice treated with anti-IL-2 receptor monoclonal antibody (PC61) conjugated with idarubicin. (1990) (0)
- Xenotransplantation remains a real clinical prospect (1999) (0)
- Molecular analysis of Ly-2/3 and L3T4 molecules. (1986) (0)
- Anti-T cell monoclonal antibodies for in vivo treatment of cardiac allograft rejection in mice. (1989) (0)
- Mannan-MUC 1 ^ Pulsed Dendritic Cell Immunotherapy : APhase I Trial in Patientswith Adenocarcinoma (2006) (0)
- The role of the various regions of the H-2 complex in enhancement and the immune response to the private H-2 alloantigens. (1973) (0)
- Cytotoxic T-Lymphocytes Derived from Patients with Breast Adenocarcinoma Recognize an Epifope Present on the Protein Core of a Mucin Molecule Preferentially Expressed by Malignant Cells1 (2006) (0)
- Prolonged survival of baboon renal allografts using idarubicin-conjugated anti-CD4 monoclonal antibodies (2000) (0)
- Cytotoxic T-Lymphocytes Derived from Patients with Breast Adenocarcinoma Recognize an Epifope Present on the Protein Core of a Mucin Molecule Preferentially Expressed by Malignant Cells 1 (2006) (0)
- Presence in unprimed mice of helper T cells specific for antigens closely related to self and their possible relevance to tumor immunology. (1981) (0)
- The cellular uptake and cytotoxicity of chlorambucil-monoclonal antibody conjugates. (1987) (0)
- The relationship between Ia antigens, lad H loci, and Ir genes: studies of an i-a mutant. (1981) (0)
- ENHANCEMENT OF SKIN GRAFTS IN THE MOUSE: THE COMBINED USE OF SPECIFIC AND NONSPECIFIC IMMUNOSUPPRESSION (1975) (0)
- Specific tumor enhancement of ly 2,3+ suppressor t cells. Abstr. (1981) (0)
- Tribute to Carl-Gustav Groth (1933-2014), first president of the International Xenotransplantation Association. (2014) (0)
- Prolonged survival of baboon renal allografts using idarubicin‐conjugated anti‐CD4 monoclonal antibodies (2000) (0)
- Letters to the Editor (0)
- Immunological reconstitution in a patient with severe combined immune deficiency using non-sibling bone marrow depleted of T cells with HuLy-m1. (1986) (0)
- Differentiation markers and accessory function of murine macrophages derived from cultured bone-marrow stem cells. (1983) (0)
- Delayed-type hypersensitivity andallograft rejection inthe mouse: correlation ofeffector cell phenotype (1982) (0)
- Expression of Ly-5.1 antigens on the effector and regulatory cells involved in cytotoxic T cell response to transplantation antigens. (1981) (0)
- Visualization of metastatic colonic tumours using monoclonal antibodies (1984) (0)
- During primary infection with dengue virus. (1984) (0)
- Immunosuppression by anti-CD8 (Ly-2.1) MAb conjugated to idarubicin: studies in the mouse heart graft model. (1990) (0)
- 258 A phase I trial in patients with solid tumours using autologous dendritic cells loaded with mannan-conjugated recombinant MUC1 protein (2004) (0)
- Highlights of the 6th Congress of the International Xenotransplantation Association, Chicago, 2001 (2002) (0)
This paper list is powered by the following services:
